Impact Of Rebates On Drug Pricing Will Diminish -- CMS Experts
Actuaries with the US Centers for Medicare and Medicaid Services predict the share of retail prescription drug costs represented by manufacturer rebates will level off in the coming years, resulting in higher drug pricing trends across government and commercial insurance.
You may also be interested in...
Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.